Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDUltragenyx Pharmaceutical Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 8 | -$1.78 | -$1.27 | -$1.56 |
| Q2 2025 | 6 | -$1.56 | -$1.10 | -$1.33 |
| Q3 2025 | 4 | -$1.53 | -$1.09 | -$1.31 |
| Q4 2025 | 6 | -$1.32 | -$0.93 | -$1.12 |
| Q1 2026 | 3 | -$1.65 | -$1.17 | -$1.40 |
| Q2 2026 | 5 | -$1.35 | -$0.95 | -$1.15 |
| Q3 2026 | 3 | -$1.24 | -$0.88 | -$1.05 |
| Q4 2026 | 5 | -$0.74 | -$0.52 | -$0.63 |
Ultragenyx Pharmaceutical Inc. Earnings Date And Information
Ultragenyx Pharmaceutical Inc. last posted its earnings results on Thursday, February 13th, 2025. The company reported $-1.39 earnings per share for the quarter, missing analysts' consensus estimates of $-1.32 by $0.07. The company had revenue of 164.88 M for the quarter and had revenue of 560.23 M for the year. Ultragenyx Pharmaceutical Inc. has generated $-6 earnings per share over the last year ($-6.29 diluted earnings per share) and currently has a price-to-earnings ratio of -6.41. Ultragenyx Pharmaceutical Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 13th, 2025 based on prior year's report dates.
Ultragenyx Pharmaceutical Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 02/19/2025 | Q4 2024 | N/A | -$1.47 | N/A | $151.86 M | $164.88 M |
| 11/05/2024 | Q3 2024 | N/A | -$1.40 | N/A | $135.28 M | $139.49 M |
| 08/01/2024 | Q2 2024 | N/A | -$1.52 | N/A | $123.20 M | $147.03 M |
| 05/02/2024 | Q1 2024 | N/A | -$2.03 | N/A | N/A | $108.83 M |
| 02/21/2024 | Q4 2023 | N/A | -$1.52 | N/A | $119.38 M | $127.39 M |
| 11/02/2023 | Q3 2023 | N/A | -$2.23 | N/A | $109.60 M | $98.05 M |
| 08/03/2023 | Q2 2023 | N/A | -$2.25 | N/A | $104.81 M | $108.31 M |
| 05/04/2023 | Q1 2023 | N/A | -$2.33 | N/A | N/A | $100.50 M |
| 02/16/2023 | Q4 2022 | N/A | -$2.16 | N/A | N/A | $103.35 M |
| 11/02/2022 | Q3 2022 | N/A | -$3.50 | N/A | $96.46 M | $90.70 M |
| 07/28/2022 | Q2 2022 | N/A | -$2.26 | N/A | $87.78 M | $89.34 M |
| 05/05/2022 | Q1 2022 | N/A | -$2.19 | N/A | N/A | $79.94 M |
| 02/15/2022 | Q4 2021 | N/A | -$1.79 | N/A | N/A | $83.39 M |
| 11/02/2021 | Q3 2021 | N/A | -$1.08 | N/A | $81.55 M | $81.65 M |
| 08/02/2021 | Q2 2021 | N/A | -$1.81 | N/A | $85.87 M | $86.98 M |
| 05/04/2021 | Q1 2021 | N/A | -$2.03 | N/A | N/A | $99.40 M |
| 02/11/2021 | Q4 2020 | N/A | -$0.37 | N/A | N/A | $91.54 M |
| 10/27/2020 | Q3 2020 | -$1.24 | -$1.13 | 0.11 | $54.96 M | $81.47 M |
| 07/31/2020 | Q2 2020 | -$1.56 | $0.41 | 1.97 | $39.34 M | $61.71 M |
| 05/06/2020 | Q1 2020 | N/A | -$2.05 | N/A | N/A | $36.31 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Ultragenyx Pharmaceutical Inc. Earnings: FAQ's
Ultragenyx Pharmaceutical Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 13th, 2025 based offlast year's report dates.
The conference call for Ultragenyx Pharmaceutical Inc.'s latest earnings report can be listened to online.
The conference call transcript for Ultragenyx Pharmaceutical Inc.'s latest earnings report can be read online.
Ultragenyx Pharmaceutical Inc. (:RARE) has a recorded annual revenue of $560.23 M.
Ultragenyx Pharmaceutical Inc. (:RARE) has a recorded net income of $-569,183,000.Ultragenyx Pharmaceutical Inc. has generated $-6.29 earnings per share over the last four quarters.
Ultragenyx Pharmaceutical Inc. (:RARE) has a price-to-earnings ratio of -6.41 and price/earnings-to-growth ratio is -8.29.